Portland, OR, June 28, 2022 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global male hypogonadism market generated $3.1 billion in 2020, and is expected to reach $5.1 billion by 2030, witnessing a CAGR of 5.1% from 2021 to 2030. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.
Increase in prevalence and incidence of testosterone deficiency in males, surge in infertility rates, and rise in awareness of male hypogonadism treatment choices among the patients drive the growth of the global male hypogonadism market. However, the availability of testosterone replacement treatment (TRT) restrains the market growth. On the other hand, technological developments present new opportunities in the coming years.
Download Sample Report- https://www.alliedmarketresearch.com/request-sample/1874
Covid-19 Scenario:
- The pandemic positively impacted the male hypogonadism market as the COVID-19 infection lowered testosterone levels in men. This led to surge in adoption of various therapies post-pandemic.
- During the initial stages of pandemic, non-elective procedures were postponed in the hospitals and clinics, due to rise in focus on surging cases of Covid-infected patients and the need to avoid the possibility of cross-contamination.
Get detailed COVID-19 impact analysis on the Male Hypogonadism Market –
